News & Trends - MedTech & Diagnostics
Stryker closes $500m Mobius Imaging and Cardan Robotics acquisition
Stryker announced its acquisition of Mobius Imaging, a leader in point-of-care imaging technology, and its sister company, Cardan Robotics.
Stryker was the first orthopedics major to bet large on robotics with the $1.68 billion acquisition of Mako Surgical in December 2013. Last month Stryker agreed to pay $370 million up front, with another $130 million on the line in milestones, for Mobius and sister company GYS Tech, which operates under the Cardan Robotics brand.
Mobius developed the Airo TruCT scanner, which won 510(k) clearance from the FDA in April 2018. Founded in 2015, Cardan is developing robotics and navigation technologies for spinal procedures.
“Mobius Imaging and Cardan Robotics bring expertise in advanced imaging and robotics, as well as a robust product pipeline, that will provide Stryker the opportunity to increase its presence in Orthopaedics, Spine and Neurotechnology,” said Spencer Stiles, Stryker’s Group President, Orthopaedics and Spine. “With this acquisition, we are positioned to make healthcare better by providing more complete procedural solutions, including sales, service, and support. We remain committed to our surgeons and helping them achieve the best possible outcomes for their patients.”
You may also like Competitive grants to turn MedTech discoveries into clinical reality
News & Trends - Biotechnology

CSL reshapes R&D while bracing for U.S. tariffs
Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]
MoreNews & Trends - MedTech & Diagnostics

Australia joins Medtronic trial in fight against resistant hypertension
Medtronic has launched an international clinical trial across Australia, the United States, and Europe to evaluate the feasibility of multi-organ […]
MoreNews & Trends - MedTech & Diagnostics

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban
Medibank has become the first Australian health insurer to pay towards pharmacogenetic testing (PGx) for eligible customers on Extras cover. […]
MoreNews & Trends - Pharmaceuticals

Global pledge shifts visibility and action for patients with advanced breast cancer
Three breast cancer organisations have united internationally to demand that people living with metastatic breast cancer (MBC) are no longer […]
More